Article in ACS infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
ACS infectious diseases · 2021
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors at 2 institutions in 1 country.
Nichole K StewartDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Marta TothDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Anastasiya StasyukStanford Synchrotron Radiation Lightsource, Stanford University, Menlo Park, California 94025, United States.
Mijoon LeeDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.ORCID 0000-0001-7432-0427
Clyde A SmithStanford Synchrotron Radiation Lightsource, Stanford University, Menlo Park, California 94025, United States.ORCID 0000-0002-1885-1511
Sergei B VakulenkoDepartment of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, Indiana 46556, United States.
University of Notre Dame · USStanford Synchrotron Radiation Lightsource · US
Funding
ZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI SCOTT, EMILY E · 1985 to 2011
$38.9M
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii InfectionsR01AI155723 · NIAID · UNIVERSITY OF NOTRE DAME · PI BUYNAK, JOHN D, VAKULENKO, SERGEI · 2021 to 2025
$3.9M
Resistance to Carbapenem Antibiotics in Acinetobacter baumanniiR01AI114668 · NIAID · UNIVERSITY OF NOTRE DAME · PI BUYNAK, JOHN D, VAKULENKO, SERGEI · 2015 to 2020
$3.1M
Antibiotics Designed to Counter Resistant 21st Century PathogensR15AI142699 · NIAID · SOUTHERN METHODIST UNIVERSITY · PI BUYNAK, JOHN D · 2019 to 2019
Avibactam is a potent diazobicyclooctane inhibitor of class A and C β-lactamases. The inhibitor also exhibits variable activity against some class D enzymes from Gram-negative bacteria; however, its interaction with recently discovered class D β-lactamases from Gram-positive bacteria has not been studied. Here, we describe microbiological, kinetic, and mass spectrometry studies of the interaction of avibactam with CDD-1, a class D β-lactamase from the clinically important pathogen
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.